$EKSO
EKSO BIONICS HOLDINGS, INC.

2014 Q4 Form 10-Q Financial Statement

#000114420414066801 Filed on November 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $1.480M $1.588M $833.8K
YoY Change 90.46%
Cost Of Revenue $930.0K $1.108M $533.0K
YoY Change 107.86%
Gross Profit $554.0K $480.0K $300.7K
YoY Change 59.62%
Gross Profit Margin 37.43% 30.23% 36.07%
Selling, General & Admin $4.110M $3.116M $1.520M
YoY Change 105.06%
% of Gross Profit 741.88% 649.17% 505.3%
Research & Development $1.300M $1.096M $453.2K
YoY Change 141.85%
% of Gross Profit 234.66% 228.33% 150.69%
Depreciation & Amortization $210.0K $210.0K
YoY Change
% of Gross Profit 37.91% 43.75%
Operating Expenses $5.410M $4.212M $1.973M
YoY Change 54000.0% 113.51%
Operating Profit -$4.856M -$3.732M -$1.672M
YoY Change 123.21%
Interest Expense $0.00 $3.000K $170.1K
YoY Change -98.24%
% of Operating Profit
Other Income/Expense, Net -$15.30M -$15.00K -$19.96K
YoY Change -24.85%
Pretax Income -$20.15M $12.02M $0.00
YoY Change 201400.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$20.16M $12.02M -$1.894M
YoY Change 201450.0% -734.87%
Net Earnings / Revenue -1361.82% 757.18% -227.15%
Basic Earnings Per Share -$0.23 $0.15 -$0.09
Diluted Earnings Per Share -$0.23 -$0.04 -$0.09
COMMON SHARES
Basic Shares Outstanding 78.61M shares 78.51M shares 21.09M shares
Diluted Shares Outstanding 83.34M shares 21.09M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.19M $7.180M $0.00
YoY Change -100.0%
Cash & Equivalents $25.19M $7.176M $227.1K
Short-Term Investments
Other Short-Term Assets $1.940M $1.700M
YoY Change
Inventory $622.0K $864.4K
Prepaid Expenses
Receivables $1.549M $1.922M
Other Receivables $0.00 $0.00
Total Short-Term Assets $29.30M $11.66M $0.00
YoY Change 814.77% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment $2.102M $1.957M
YoY Change 33.46%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $54.76K
YoY Change -100.0%
Total Long-Term Assets $4.174M $3.756M $0.00
YoY Change 23.45%
TOTAL ASSETS
Total Short-Term Assets $29.30M $11.66M $0.00
Total Long-Term Assets $4.174M $3.756M $0.00
Total Assets $33.47M $15.42M $0.00
YoY Change 408.41% -100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $783.0K $1.077M
YoY Change -47.77%
Accrued Expenses $2.378M $1.322M $0.00
YoY Change 65.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -50.0%
Long-Term Debt Due $40.00K $40.00K
YoY Change
Total Short-Term Liabilities $6.614M $5.896M $10.00K
YoY Change -45.13% 58860.05% -50.0%
LONG-TERM LIABILITIES
Long-Term Debt $80.00K $90.00K $0.00
YoY Change
Other Long-Term Liabilities $165.0K $15.36M
YoY Change
Total Long-Term Liabilities $165.0K $15.45M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.614M $5.896M $10.00K
Total Long-Term Liabilities $165.0K $15.45M $0.00
Total Liabilities $10.67M $21.34M $10.00K
YoY Change -31.72% 213300.19% -50.0%
SHAREHOLDERS EQUITY
Retained Earnings -$71.80M -$51.65M
YoY Change 88.79%
Common Stock $102.0K $78.58K
YoY Change 385.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.80M -$5.922M -$10.00K
YoY Change
Total Liabilities & Shareholders Equity $33.47M $15.42M $0.00
YoY Change 408.41% -100.0%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$20.16M $12.02M -$1.894M
YoY Change 201450.0% -734.87%
Depreciation, Depletion And Amortization $210.0K $210.0K
YoY Change
Cash From Operating Activities -$2.710M -$3.590M $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$570.0K -$250.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$100.0K $0.00
YoY Change
Cash From Investing Activities -$680.0K -$240.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.40M 40.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.710M -3.590M 0.000
Cash From Investing Activities -680.0K -240.0K
Cash From Financing Activities 21.40M 40.00K 0.000
Net Change In Cash 18.01M -3.790M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$2.710M -$3.590M $0.00
Capital Expenditures -$570.0K -$250.0K
Free Cash Flow -$2.140M -$3.340M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2013Q4 us-gaap Assets Current
AssetsCurrent
3203203 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1957324 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1575286 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1921574 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
549469 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
864397 USD
CY2014Q3 us-gaap Deferred Costs
DeferredCosts
1743865 USD
CY2013Q4 us-gaap Deferred Costs
DeferredCosts
803298 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54764 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21114783 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78584173 shares
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
330798 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
250998 USD
CY2014Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
1369087 USD
CY2013Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
768599 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
11662124 USD
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
25923873 shares
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
805306 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
725096 USD
CY2013Q4 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
103735 USD
CY2014Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
USD
CY2014Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
USD
CY2014Q3 us-gaap Notes Receivable Related Parties Current
NotesReceivableRelatedPartiesCurrent
USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7176268 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51645635 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38031619 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-5921942 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-36372708 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15418077 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6583937 USD
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78584173 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21114783 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
78584 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
21114 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
45645109 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1637797 USD
CY2013Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
27324208 USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60952000 shares
CY2014Q3 us-gaap Liabilities
Liabilities
21340019 USD
CY2013Q4 us-gaap Liabilities
Liabilities
15632437 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
33523600 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
25923872 shares
CY2014Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
88401 USD
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
866950 USD
CY2014Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
11819450 USD
CY2013Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
377747 USD
CY2014Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
96553 USD
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
123709 USD
CY2014Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
1323 USD
CY2013Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
5293 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5896005 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12054920 USD
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3439610 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2209111 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15539 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20937488 shares
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1077073 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1498680 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1321960 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1430799 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3454906 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2419226 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1002150 USD
CY2014Q3 us-gaap Assets
Assets
15418077 USD
CY2013Q4 us-gaap Assets
Assets
6583937 USD
CY2014Q3 us-gaap Notes Payable Current
NotesPayableCurrent
40743 USD
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1638505 USD
CY2013Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
5062417 USD
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
788299 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
416682 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2005592 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1138995 USD
CY2014Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
799884 USD
CY2013Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
417082 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
300721 USD
us-gaap Gross Profit
GrossProfit
1004860 USD
us-gaap Gross Profit
GrossProfit
720197 USD
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83336371 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21085283 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74943169 shares
CY2013Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33063 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-33063 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74943169 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20937488 shares
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78513144 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21085283 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1679393 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1552825 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
12024361 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1893924 USD
us-gaap Net Income Loss
NetIncomeLoss
-13614016 USD
us-gaap Net Income Loss
NetIncomeLoss
-9090634 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19961 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-44610 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40815 USD
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15756183 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-221946 USD
CY2014Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
15773100 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1205900 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1021 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1184 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3897 USD
us-gaap Interest Expense
InterestExpense
432780 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
2399 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
170106 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4003 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-11934623 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7537809 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-223 USD
us-gaap Inventory Write Down
InventoryWriteDown
21420 USD
us-gaap Cost Of Services
CostOfServices
1018801 USD
us-gaap Inventory Write Down
InventoryWriteDown
USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
6974 USD
us-gaap Interest Expense
InterestExpense
1482950 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
4211611 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1972699 USD
us-gaap Operating Expenses
OperatingExpenses
12939483 USD
us-gaap Operating Expenses
OperatingExpenses
8258006 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3731822 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1671978 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2563806 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2164840 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1473951 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
752215 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5354009 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2854332 USD
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1641280 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
767316 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5021668 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3238834 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1096380 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
453168 USD
us-gaap Cost Of Services
CostOfServices
1431802 USD
CY2014Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1108394 USD
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
533043 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2842087 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1793808 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
578737 USD
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
245575 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1410285 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
775007 USD
CY2014Q3 us-gaap Cost Of Services
CostOfServices
529657 USD
CY2013Q3 us-gaap Cost Of Services
CostOfServices
287468 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1841355 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1375010 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1588183 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
833764 USD
us-gaap Sales Revenue Net
SalesRevenueNet
3846947 USD
us-gaap Sales Revenue Net
SalesRevenueNet
2514005 USD
us-gaap Depreciation
Depreciation
535400 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
USD
us-gaap Depreciation
Depreciation
342148 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
USD
us-gaap Interest Expense Debt
InterestExpenseDebt
162563 USD
us-gaap Interest Income Other
InterestIncomeOther
3525 USD
us-gaap Interest Paid
InterestPaid
136085 USD
us-gaap Interest Paid
InterestPaid
306792 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1698 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
13903 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
27324208 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6285033 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6370962 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1511564 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1738662 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227098 USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
USD
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
4294259 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22027089 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51634 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-813702 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-49627 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6761753 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
103735 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19479828 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5299816 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2547261 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1046077 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2000000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12295164 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
917437 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49627 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-422328 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194793 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-108119 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-169504 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2266179 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1267074 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
160722 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
339147 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80072 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80658 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
1541055 USD
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
384283 USD
us-gaap Share Based Compensation
ShareBasedCompensation
810399 USD
us-gaap Share Based Compensation
ShareBasedCompensation
278155 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1372105 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-122954 USD
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
-27156 USD
us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
-27154 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
191111 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
126010 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-799195 USD
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0;">&#160;<strong>Common Stock Warrants</strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">We account for the common stock warrants issued in connection with our Merger, (see <em>Note 3, The Merger, Offering and Other Related Matters,) </em>in accordance with the guidance in Accounting Standards Codification (&#147;ASC&#148;) 815-40. Under ASC 815-40 the warrants do not meet the criteria for equity treatment and are recorded as a liability. The warrants have an anti-dilution clause that allows for a decrease in the exercise price of the warrants if the Company issues additional shares of common stock without consideration or for consideration per share less than the common stock warrant's exercise price. Accordingly, we classified the warrant instruments as liabilities at their fair market value at the date of the Merger and will re-measure the warrants at each balance sheet date until they are exercised or they expire. Any change in the fair value is recognized as a gain (loss) on warrant liability in our consolidated statement of operations.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">The fair value of the warrant liability was determined using the binomial lattice pricing model. This model is dependent upon several variables such as the instrument's term, expected strike price, current stock price, risk-free interest rate estimated over the expected term, and the estimated volatility of our stock over the term of the warrant. The expected strike price is estimated based on a weighted average probability analysis of the strike price changes expected during the term as a result of the anti-dilution clause in the agreement. The risk-free rate is based on U.S. Treasury securities with similar maturities as the expected terms of the warrants. The volatility is estimated based on blending the volatility rates for a number of similar publicly-traded companies.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">&#160;</p> </div>
CY2014Q3 us-gaap Deferred Revenue
DeferredRevenue
6894516 USD
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
4628337 USD
CY2013Q4 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
1571897 USD
CY2014Q3 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
3112952 USD
us-gaap Use Of Estimates
UseOfEstimates
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><strong>Use of Estimates</strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying footnotes. These estimates include, but are not limited to: revenue recognition, useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of warrant liabilities, valuation of common and preferred stock options, and the valuation of common stock for purposes of determining stock-based compensation and contingencies. Actual results could differ from those estimates.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> </div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><strong>Concentration of Credit Risk and Other Risks and Uncertainties</strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. We maintain our cash accounts in excess of federally insured limits. However, we believe we are not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">We extend credit to customers in the normal course of business and perform ongoing credit evaluations of our customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. We do not require collateral from our customers to secure accounts receivable.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. We review accounts receivable for collectability and provide an allowance for credit losses, as needed. We have not experienced any material losses related to accounts receivable as of September 30, 2014 and December 31, 2013.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. We do not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, we have not experienced significant gains or losses upon settling foreign contracts.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of September 30, 2014, we had <font>one</font> customer with accounts receivable balances totaling <font>10</font>% or more of our total accounts receivable (<font>24</font>%), compared with <font>two</font> customers as of December 31, 2013 (<font>28</font>% and <font>19</font>%).</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">&#160;</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">In the three months ended September 30, 2014, we had <font>three</font> customers with sales balances of <font>10</font>% or more of our total customer sales (<font>19</font>%, <font>17</font>%, and <font>17</font>%), compared with <font>two</font> customers in the three months ended September 30, 2013 (<font>22</font>% and <font>16</font>%). In the nine months ended September 30, 2014, we had <font>one</font> customer with a sales balance of <font>17</font>% of our total customer sales compared to one customer in the nine months ended September 30, 2013 (<font>13</font>%).</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">&#160;</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0261 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0174 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0261 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y10M13D
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
13847 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M13D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M29D
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2400000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M2D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9276442 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.69
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2645583 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4710443 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.41
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2093011 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
127542 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.47
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9910969 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.72
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2704099 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3461391 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.35
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
228306 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
749901 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
810399 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
278155 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12131613 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7555327 shares
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117330 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
107633 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0168 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.66 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6566 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6646 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.68 pure
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12024361 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1893924 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13614016 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9090634 USD
CY2014Q3 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
-15773100 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3748739 USD
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7335135 shares
CY2013 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
5280368 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
750653 shares
CY2014Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4072574 shares
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1893924 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13614016 USD
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7335135 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9090634 USD
CY2013 us-gaap Stockholders Equity Note Spinoff Transaction
StockholdersEquityNoteSpinoffTransaction
USD
CY2013 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
USD
CY2014Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-26144245 USD
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
839832 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
657628 USD
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
274389 USD
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421966 USD
CY2014Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
140335 USD
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
288110 USD
CY2014Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
67404 USD
CY2013Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
62283 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
812 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
136380 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65593 USD
CY2013 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
189 USD
CY2013 ekso Stock Issued During Prior Period Value Stock Options Exercised Early
StockIssuedDuringPriorPeriodValueStockOptionsExercisedEarly
3974 USD
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
USD
ekso Registration Payment Arrangement Potential Adverse Consequences Offering Price Percentage
RegistrationPaymentArrangementPotentialAdverseConsequencesOfferingPricePercentage
0.010 pure
ekso Registration Payment Arrangement Potential Adverse Consequences Maximum Offering Price Percentage
RegistrationPaymentArrangementPotentialAdverseConsequencesMaximumOfferingPricePercentage
0.08 pure
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
4679 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
390618 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-11887374 USD
CY2014Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1910 USD
ekso Equity Units Warrants Per Unit
EquityUnitsWarrantsPerUnit
1 shares
CY2014Q1 ekso Equity Issued During Period Units New Issues
EquityIssuedDuringPeriodUnitsNewIssues
20580000 shares
CY2014Q1 ekso Stock Issued During Period Value Conversion Of Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
27324208 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-8764603 USD
CY2014Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25300000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
281987 USD
CY2014Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5082578 USD
CY2014Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
95760 USD
CY2013 ekso Equity Interest
EquityInterest
0.068 pure
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25300000 USD
ekso Equity Units Shares Per Unit
EquityUnitsSharesPerUnit
1 shares
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4250744 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
-10613550 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
6849441 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67196 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
34962 USD
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
810399 USD
us-gaap Net Income Loss
NetIncomeLoss
-13614016 USD
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
USD
CY2014Q3 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
USD
ekso Equity Issued During Period Units New Issues
EquityIssuedDuringPeriodUnitsNewIssues
30300000 shares
ekso Equity Issued During Period Units New Issues Price Per Unit
EquityIssuedDuringPeriodUnitsNewIssuesPricePerUnit
1.00
ekso Equity Issued During Period Units Issued For Cash
EquityIssuedDuringPeriodUnitsIssuedForCash
25300000 shares
CY2013 ekso Stock Issued During Period Shares Acquisitions Previously Held
StockIssuedDuringPeriodSharesAcquisitionsPreviouslyHeld
4500600 shares
CY2013 ekso Stock Issued During Period Shares Acquisitions New Issues
StockIssuedDuringPeriodSharesAcquisitionsNewIssues
779768 shares
CY2014Q1 ekso Equity Issued During Period Units New Issues Price Per Unit
EquityIssuedDuringPeriodUnitsNewIssuesPricePerUnit
1.00
CY2014Q1 ekso Equity Issued During Period Units New Issues
EquityIssuedDuringPeriodUnitsNewIssues
9720000 shares
CY2014Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
1.00
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
3030000 USD
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
14410000 shares
CY2014Q1 ekso Equity Units Shares Per Unit
EquityUnitsSharesPerUnit
1 shares
CY2014Q1 ekso Equity Units Warrants Per Unit
EquityUnitsWarrantsPerUnit
1 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1 shares
CY2014Q1 ekso Equity Units Warrants Per Unit
EquityUnitsWarrantsPerUnit
1 shares
CY2014Q1 ekso Equity Units Shares Per Unit
EquityUnitsSharesPerUnit
1 shares
CY2014Q1 ekso Equity Issued During Period Units New Issues Price Per Unit
EquityIssuedDuringPeriodUnitsNewIssuesPricePerUnit
1.00
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000000 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3600000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5600000 USD
CY2014Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3100000 USD
dei Entity Registrant Name
EntityRegistrantName
EKSO BIONICS HOLDINGS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001549084
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78608410 shares

Files In Submission

Name View Source Status
0001144204-14-066801-index-headers.html Edgar Link pending
0001144204-14-066801-index.html Edgar Link pending
0001144204-14-066801.txt Edgar Link pending
0001144204-14-066801-xbrl.zip Edgar Link pending
ekso-20140930.xml Edgar Link completed
ekso-20140930.xsd Edgar Link pending
ekso-20140930_cal.xml Edgar Link unprocessable
ekso-20140930_def.xml Edgar Link unprocessable
ekso-20140930_lab.xml Edgar Link unprocessable
ekso-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v392855_10q.htm Edgar Link pending
v392855_ex31-1.htm Edgar Link pending
v392855_ex31-2.htm Edgar Link pending
v392855_ex32-1.htm Edgar Link pending
v392855_ex32-2.htm Edgar Link pending